1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metabolic tumor volume to predict event free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy
    Meeting Abstract

    Gavane, S. C.; Ito, K.; Moskowitz, C. H.; Moskowitz, A. J.; Schoder, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Outcomes of patients 60 and older with ALL: Analysis of the SEER database
    Meeting Abstract

    Geyer, M. B.; Hsu, M.; Devlin, S.; Douer, D.; Park, J. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)
    Meeting Abstract

    Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease
    Meeting Abstract

    Emile, J. F.; Cohen-Aubart, F.; Baillou, C.; Roos-Weil, D.; Papo, M.; Helias-Rodzewicz, Z.; Abdel-Wahab, O. I.; Bernard, O. A.; Amoura, Z.; Lemoine, F. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Davids, M. S.; Roberts, A. W.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Kipps, T. J.; Pagel, J. M.; Puvvada, S. D.; Gressick, L. A.; Zhu, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Davids, M. S.; Gerecitano, J. F.; Potluri, J.; Cerri, E.; Kim, S. Y.; Steinberg, M.; Verdugo, M.; Busman, T. A.; Enschede, S. H.; Mobasher, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A randomized, phase 2 trial of denintuzumab mafodotin and RICE vs RICE alone in the treatment of patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant (ASCT)
    Meeting Abstract

    Chen, R. W.; Jacobsen, E. D.; Kostic, A.; Liu, T.; Moskowitz, C. H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Phase 2 KEYNOTE-087 study
    Meeting Abstract

    Chen, R. W.; Zinzani, P. L.; Fanale, M. A.; Armand, P.; Johnson, N.; Ribrag, V.; Radford, J. A.; Tomita, A.; Shipp, M. A.; Wang, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save